Latest News

Takeda Oncology Research Award 2018 to Rocio Sotillo

A certain form of lung cancer is characterized by two genes that are accidentally fused. The fusion produces a growth signal for the cells. These tumors respond well to a targeted drug that deprives the cancer cells of the growth stimulus. Several molecular variants of cancer-promoting gene fusion exist. Rocio Sotillo of the German Cancer Research Center has discovered that one of these variants is associated with a more aggressive disease, which also rapidly develops resistance to the cancer drug. For these results Sotillo has now received the Takeda Oncology Research Prize 2018, endowed with 30,000 euros.

Funding

Machine Learning to Accellerate Drug Research

The European Research Council (ERC) is awarding a "proof-of-concept grant" to scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Heidelberg University for the first time to enable them to develop new drugs more cheaply and quickly using image-based analyses.

Breast Cancer

Towards individualized therapy

Breast cancer is as manifold as are those who are affected. Therefore, scientists and physicians from the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the National Center for Tumor Diseases (NCT) in Heidelberg are generating genetic profiles from metastatic tissue samples before they choose, on this basis, an appropriate therapy tailored to the individual patient. In this way, they endeavor to improve curative chances and lower the risk of side effects.

We are asking for your support

Your Donation for Cancer Research
2018 Erwin Schrödinger Prize

Enhanced detection and treatment of prostate cancer

This year's Stifterverband Science Award – Erwin Schrödinger Prize goes to an interdisciplinary team of researchers from Heidelberg. Scientists Matthias Eder, Michael Eisenhut, Uwe Haberkorn and Klaus Kopka have jointly developed a method that facilitates more reliable diagnosis as well as more specific treatment of prostate cancer.

Latest News

Sugar metabolism controls intestinal regeneration

Scientists from the German Cancer Research Center and Heidelberg University have discovered a surprising connection between sugar metabolism and the adaptation of intestinal tissue to the nutritional state.

© Fotolia
Latest News

A healthy lifestyle reduces the risk of colon cancer - regardless of the genetic risk profile

The risk of developing bowel cancer depends, among other things, on lifestyle. Scientists from the German Cancer Research Center were able to show that everyone can reduce their personal risk of colon cancer by combining as many of five healthy lifestyles as possible: non-smoking, low alcohol consumption, a healthy diet, sufficient physical activity and normal body weight. This applies regardless of the genetic risk of bowel cancer. Even those who have a slightly increased risk due to genetic factors can reduce their risk by following a healthy lifestyle.

Information


Search for research topic

Hopp Children’s Cancer Center (KiTZ)

New approach uncovers tumor promoting signaling pathway in common children’s brain tumor

A study conducted by researchers of the "Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ)" together with colleagues from the Institute Curie (Orsay, France) and the University Hospital Düsseldorf discovered a novel signal transducer promoting medulloblastoma growth. Here, the teams combined two state-of-the-art molecular analysis methods in a project supported by the German Cancer Consortium (DKTK). Their combination approach revealed novel therapeutic targets for a difficult-to-treat brain tumor in children.

DKTK

Colorectal cancer: Tipping the scales

Tumors of the colon are among the most prevalent cancers. Researchers at LMU and the German Cancer Consortium (DKTK) have now shown that a protein promotes the formation of intestinal stem cells and thereby contributes to the initiation of tumorigenesis in the colon.

DKTK

microRNAs predict recurrence risk of head and neck tumors

A new method predicts the course of HPV-negative head and neck cancer after radiation chemotherapy. According to a recent article in the journal 'Clinical Cancer Research', five microRNAs (miRNAs) can provide the decisive data. The work was conducted at the Helmholtz Zentrum München and the University Hospital of the Ludwig-Maximilians-Universität München (LMU) in close collaboration with the German Cancer Consortium (DKTK).

DKFZ - A Video

to top